JCU - January 2022 - 61

Rodrigues et al.
61
residual volumes and PSA density, that indicates prostate
enlargement, were attributed to bladder outlet obstruction.
Further studies are warranted to establish the real influence
of specific risk factors, such as patient age, comorbidity profile,
prostate size and present antibiotic prophylaxis regimens
on prostate biopsy complication rate.27,28 In our
opinion, future perspectives should consider a combination
of augmented and target antibiotic prophylaxis, adopting
pre-biopsy rectal swabs as a standard of care.
Conflicting interests
The authors declare that there is no conflict of interest.
Funding
The authors received no financial support for the research,
authorship, and/or publication of this article.
Ethical approval
All procedures performed in studies involving human participants
were in accordance with the ethical standards of the institutional
and national research
committee (HCRP,
References
1. Taitt HE. Global trends and prostate cancer: a review of
incidence, detection, and mortality as Influenced by race,
ethnicity, and geographic Location. Am J Mens Health
2018; 12(6): 1807-1823.
2. Helgstrand JT, Røder MA, Klemann N, et al. Diagnostic
characteristics of lethal prostate cancer. Eur J Cancer 2017;
84: 18-26.
3. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis
and overtreatment of prostate cancer. Eur Urol 2014; 65:
1046-1055.
4. Omer A and Lamb AD. Optimizing prostate biopsy techniques.
Curr Opin Urol 2019; 29(6): 578-86.
5. Russo GI, Regis F, Castelli T, et al. A systematic review and
meta-analysis of the diagnostic accuracy of prostate health
index and 4-Kallikrein panel score in predicting overall and
high-grade prostate cancer. Clin Genitourin Cancer 2017;
15(4): 429-439.
6. Kretschmer A and Tilki D. Biomarkers in prostate cancer:
current clinical utility and future perspectives. Crit Rev
Oncol Hematol 2017; 120: 180-193.
number
3405/2017) and with the Helsinki declaration (as revised in
Fortaleza, Brazil, October 2013) and its later amendments or
comparable ethical standards. This article does not contain any
studies with animals performed by any of the authors. For all
participants of this study, collection of informed consents was
dismissed by the institutional research committee.
Informed consent
Informed consent for patient information to be published in this
article was not obtained because of the retrospective design with
unidentified data collection.
Guarantor
AAR
Contributorship
AAR, VM, VSdOA, ABN, AJC, ST and RBd contributed to the
study conception, design and data analysis.
EVdA, RRM, RNF, ABN, VSdOA, GCFreire, HAS and SCdS
performed the data collection and/or data analysis.
All authors read and approved the final version of the
manuscript.
Acknowledgements
We would like to thank Mrs Miriam Cristina Marchioreto de
Oliveira, RN. Marilene Simeão, Manager, Chief Nurse
Practitioner of Medical Specialties, Outpatients Clinics -
Barretos, and Dr Tales Rubens de Nadai, Director of Américo
Brasiliense State Hospital for their support of this study.
ORCID iD
Antônio Antunes Rodrigues
-5836
https://orcid.org/0000-0002-3908
7. Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS
Prostate Imaging - Reporting and Data System: 2015,
Version 2. Eur Urol 2016; 69(1): 16-40.
8. Giganti F and Moore CM. MRI in early detection of prostate
cancer. Curr Opin Urol 2019; 29(6): 563-568.
9. Pinsky PF, Parnes HL and Andriole G. Mortality and
complications after prostate biopsy in the Prostate, Lung,
Colorectal and Ovarian Cancer Screening (PLCO) trial.
BJU Int 2014; 113(2): 254-259.
10. Fontana M, Boeri L and Montanari E. Update on techniques
to prevent infections associated with prostate needle biopsy.
Curr Opin Urol 2018; 28(4): 392-397.
11. Scott S, Harris PN, Williamson DA, et al. The effectiveness
of targeted relative to empiric prophylaxis on infectious complications
after transrectal ultrasound-guided prostate biopsy:
a meta-analysis. World J Urol 2018; 36(7): 1007-1017.
12. Wu YP, Li XD, Ke ZB, et al. Risk factors for infectious
complications following transrectal ultrasound-guided prostate
biopsy. Infect Drug Resist 2018; 11: 1491-1497.
13. European Medicines Agency, European Commission final
decision. Disabling and potentially permanent side effects
lead to suspension or restrictions of quinolone and fluoroquinolone
antibiotics, https://www.ema.europa.eu/en/
documents/referral/quinolone-fluoroquinolone-article31-referral-disabling-potentially-permanent-side-effectslead_en.pdf
(2019, accessed on 18 February 2019).
14. Dall'Oglio MF, Crippa A, Ferreira Faria E, et al. (2011)
Diretrizes de Câncer de Próstata. Rio de Janeiro: Sociedade
Brasileira de Urologia, 2011 [in Portuguese].
15. Charlson M, Szatrwoski TP, Peterson J, et al. Validation
of a combined comorbidity index. J Clin Epidemiol 1994;
47(11): 1245-1251.
16. Daskivich TJ, Kwan L, Dash A, et al. An age adjusted
comorbidity index to predict long-term, other cause mortality
in men with prostate cancer. J Urol 2015; 194(1): 73-78.
17. van den Heuvel S, Loeb S, Zhu X, et al. Complications of
initial prostate biopsy in a European randomized screening
trial. Am J Clin Exp Urol 2013; 1(1): 66-71.
https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf https://www.ema.europa.eu/en/documents/referral/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf https://www.orcid.org/0000-0002-3908-5836 https://www.orcid.org/0000-0002-3908-5836

JCU - January 2022

Table of Contents for the Digital Edition of JCU - January 2022

Contents
JCU - January 2022 - Cover1
JCU - January 2022 - Contents
JCU - January 2022 - 2
JCU - January 2022 - 3
JCU - January 2022 - 4
JCU - January 2022 - 5
JCU - January 2022 - 6
JCU - January 2022 - 7
JCU - January 2022 - 8
JCU - January 2022 - 9
JCU - January 2022 - 10
JCU - January 2022 - 11
JCU - January 2022 - 12
JCU - January 2022 - 13
JCU - January 2022 - 14
JCU - January 2022 - 15
JCU - January 2022 - 16
JCU - January 2022 - 17
JCU - January 2022 - 18
JCU - January 2022 - 19
JCU - January 2022 - 20
JCU - January 2022 - 21
JCU - January 2022 - 22
JCU - January 2022 - 23
JCU - January 2022 - 24
JCU - January 2022 - 25
JCU - January 2022 - 26
JCU - January 2022 - 27
JCU - January 2022 - 28
JCU - January 2022 - 29
JCU - January 2022 - 30
JCU - January 2022 - 31
JCU - January 2022 - 32
JCU - January 2022 - 33
JCU - January 2022 - 34
JCU - January 2022 - 35
JCU - January 2022 - 36
JCU - January 2022 - 37
JCU - January 2022 - 38
JCU - January 2022 - 39
JCU - January 2022 - 40
JCU - January 2022 - 41
JCU - January 2022 - 42
JCU - January 2022 - 43
JCU - January 2022 - 44
JCU - January 2022 - 45
JCU - January 2022 - 46
JCU - January 2022 - 47
JCU - January 2022 - 48
JCU - January 2022 - 49
JCU - January 2022 - 50
JCU - January 2022 - 51
JCU - January 2022 - 52
JCU - January 2022 - 53
JCU - January 2022 - 54
JCU - January 2022 - 55
JCU - January 2022 - 56
JCU - January 2022 - 57
JCU - January 2022 - 58
JCU - January 2022 - 59
JCU - January 2022 - 60
JCU - January 2022 - 61
JCU - January 2022 - 62
JCU - January 2022 - 63
JCU - January 2022 - 64
JCU - January 2022 - 65
JCU - January 2022 - 66
JCU - January 2022 - 67
JCU - January 2022 - 68
JCU - January 2022 - 69
JCU - January 2022 - 70
JCU - January 2022 - 71
JCU - January 2022 - 72
JCU - January 2022 - 73
JCU - January 2022 - 74
JCU - January 2022 - 75
JCU - January 2022 - 76
JCU - January 2022 - 77
JCU - January 2022 - 78
JCU - January 2022 - Cover3
JCU - January 2022 - Cover4
https://www.nxtbookmedia.com